@EricSpracklen Another issue about this current market is that the new builds are terrible. They have so many problems and are low quality. You are paying premium for corpse houses or trash new builds. It’s just bad all around.
@JacobMolBio@OmicsOmicsBlog How do you get past the blockers for engineering? Is it a special license? If i tell it im working on protein design it boots me from opus to haiku
@rlsayar@natashamalpani Also working on it. There’s also another issue with the data. It’s fundamentally flawed at the data collection side. You need an entire infrastr built around it that doesn’t exist and will take a while to build.
All of this is just massive cope. AI agents are good. Useful. But many times they produce massive documents full of errors. Big time CEO guys will not even take the time or have the time to read it but see these 40 page documents and are to amount of work=quality of work. Lawsuits incoming.
At @plasmidsaurus, we discovered our $50, 3 day TAT RNA-seq service can also detect mycoplasma contamination from several prominent species, and we've already alerted over a hundred labs to likely contamination. We're working on adding this to the service for free very soon.
@CRISPR_LuCas I don’t understand the biotech trend of hand waiving delivery. Delivery IS the problem. Mosaicism is a huge issue and the heterogeneity in expression through AAV mediated gene therapy can cause worse outcomes for whatever is being treated.
@steffingomes@celinehalioua "CURING ALL CANCERS" is not good marketing. Their approach works in cell culture (maybe) and they hand-wave delivery and specificity which is paramount for success. There are so many biotechs that are in desperate need of funds and have more than just a fancy pitch deck.